Acquisition PotentialOncology acquisition brings an interesting Phase II asset with blockbuster peak sales potential, underscored by an analyst's BUY recommendation with an increased price objective.
Pipeline ProgressUpcoming Phase II data for GEN1046 and potential Phase III trial details are highly anticipated, reflecting the company's progress and bolstering confidence in its growth prospects.
Regulatory SupportFDA briefing documents are very supportive of the use of a surrogate marker, which could positively influence JNJ's opt-in decision for Hexabody CD38, providing a faster and cheaper route to market.